Analysts’ Recent Ratings Updates for Maze Therapeutics (MAZE)

A number of research firms have changed their ratings and price targets for Maze Therapeutics (NASDAQ: MAZE):

• 1/28/2026 – Maze Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 1/25/2026 – Maze Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/22/2026 – Maze Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 1/17/2026 – Maze Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 1/16/2026 – Maze Therapeutics had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a “buy” rating on the stock.
• 12/19/2025 – Maze Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $46.00 price target on the stock.
• 12/18/2025 – Maze Therapeutics was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
• 12/13/2025 – Maze Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 200,000 shares of company stock valued at $8,254,792.

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.